NZ603895A - Novel phosphodiesterase inhibitors - Google Patents
Novel phosphodiesterase inhibitorsInfo
- Publication number
- NZ603895A NZ603895A NZ603895A NZ60389511A NZ603895A NZ 603895 A NZ603895 A NZ 603895A NZ 603895 A NZ603895 A NZ 603895A NZ 60389511 A NZ60389511 A NZ 60389511A NZ 603895 A NZ603895 A NZ 603895A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- difluoromethoxy
- phosphodiesterase inhibitors
- novel phosphodiesterase
- benzodioxole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35820910P | 2010-06-24 | 2010-06-24 | |
| PCT/DK2011/000069 WO2011160632A1 (en) | 2010-06-24 | 2011-06-24 | Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603895A true NZ603895A (en) | 2014-10-31 |
Family
ID=44351701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603895A NZ603895A (en) | 2010-06-24 | 2011-06-24 | Novel phosphodiesterase inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8980905B2 (enExample) |
| EP (2) | EP3070091B1 (enExample) |
| JP (2) | JP6174997B2 (enExample) |
| KR (1) | KR101864578B1 (enExample) |
| CN (1) | CN102958937B (enExample) |
| AU (1) | AU2011269429B2 (enExample) |
| BR (1) | BR112012032813B1 (enExample) |
| CA (1) | CA2802895C (enExample) |
| CY (2) | CY1117862T1 (enExample) |
| DK (2) | DK3070091T3 (enExample) |
| ES (2) | ES2733092T3 (enExample) |
| HR (2) | HRP20160919T1 (enExample) |
| HU (2) | HUE030081T2 (enExample) |
| IL (1) | IL223329A (enExample) |
| LT (2) | LT3070091T (enExample) |
| MX (1) | MX2012014131A (enExample) |
| MY (1) | MY157481A (enExample) |
| NZ (1) | NZ603895A (enExample) |
| PL (2) | PL2585469T3 (enExample) |
| PT (2) | PT3070091T (enExample) |
| RS (2) | RS58945B1 (enExample) |
| RU (1) | RU2583787C2 (enExample) |
| SG (1) | SG186140A1 (enExample) |
| SI (2) | SI3070091T1 (enExample) |
| TR (1) | TR201909709T4 (enExample) |
| TW (1) | TWI507410B (enExample) |
| UA (1) | UA109140C2 (enExample) |
| WO (1) | WO2011160632A1 (enExample) |
| ZA (1) | ZA201209031B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9855285B2 (en) * | 2012-11-30 | 2018-01-02 | Leo Pharma A/S | Method of inhibiting the expression of IL-22 in activated T-cells |
| CA2953284A1 (en) * | 2014-06-23 | 2015-12-30 | Leo Pharma A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CA3007432A1 (en) * | 2015-12-18 | 2017-06-22 | Leo Pharma A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| WO2018234299A1 (en) * | 2017-06-20 | 2018-12-27 | Leo Pharma A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| CN111727191B (zh) | 2017-12-15 | 2024-01-05 | 联合疗法公司 | 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| IL284815B2 (en) * | 2019-01-15 | 2025-10-01 | Union Therapeutics As | Modified-release tablet formulations containing phosphodiesterase inhibitors |
| EP4003343A1 (en) * | 2019-07-24 | 2022-06-01 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
| CN112552276B (zh) * | 2019-09-25 | 2023-03-21 | 中国科学院上海药物研究所 | 苯并氧杂卓-5-酮类化合物及其制备方法和用途 |
| AU2022245186A1 (en) | 2021-03-22 | 2023-10-05 | UNION therapeutics A/S | Treatment of hidradenitis suppurativa with orismilast |
| GB202205715D0 (en) | 2022-04-19 | 2022-06-01 | Union Therapeutics As | Treatment of neutrophilic dermatoses |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100331255B1 (ko) | 1993-07-02 | 2002-10-25 | 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 | 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도 |
| GB9507297D0 (en) | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
| AU705690B2 (en) | 1995-05-19 | 1999-05-27 | Kyowa Hakko Kogyo Co. Ltd. | Oxygen-containing heterocyclic compounds |
| CA2252537A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Benzofuran carboxamides and their therapeutic use |
| WO1998022455A1 (en) | 1996-11-19 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Oxygenic heterocyclic compounds |
| JP2005060375A (ja) * | 2003-07-28 | 2005-03-10 | Kyowa Hakko Kogyo Co Ltd | 含酸素複素環化合物 |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EA014956B1 (ru) * | 2004-12-17 | 2011-04-29 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений |
| UA98639C2 (en) * | 2007-02-28 | 2012-06-11 | Лео Фарма А/С | Phosphodiesterase inhibitors |
| JP5501770B2 (ja) * | 2007-02-28 | 2014-05-28 | レオ ファーマ アクティーゼルスカブ | 新規ホスホジエステラーゼ阻害剤 |
| PT2794603T (pt) * | 2011-12-21 | 2016-07-26 | Leo Pharma As | [1,2,4] triazolopiridinas e seu uso como inibidores de fosfodiesterase |
-
2011
- 2011-06-24 UA UAA201300812A patent/UA109140C2/uk unknown
- 2011-06-24 SI SI201131743T patent/SI3070091T1/sl unknown
- 2011-06-24 RS RS20190851A patent/RS58945B1/sr unknown
- 2011-06-24 MY MYPI2012005553A patent/MY157481A/en unknown
- 2011-06-24 HR HRP20160919TT patent/HRP20160919T1/hr unknown
- 2011-06-24 ES ES16020112T patent/ES2733092T3/es active Active
- 2011-06-24 JP JP2013515698A patent/JP6174997B2/ja active Active
- 2011-06-24 EP EP16020112.5A patent/EP3070091B1/en active Active
- 2011-06-24 DK DK16020112.5T patent/DK3070091T3/da active
- 2011-06-24 HU HUE11729889A patent/HUE030081T2/en unknown
- 2011-06-24 RS RS20160581A patent/RS55104B1/sr unknown
- 2011-06-24 PT PT16020112T patent/PT3070091T/pt unknown
- 2011-06-24 PL PL11729889T patent/PL2585469T3/pl unknown
- 2011-06-24 NZ NZ603895A patent/NZ603895A/en unknown
- 2011-06-24 PT PT117298893T patent/PT2585469T/pt unknown
- 2011-06-24 SG SG2012088761A patent/SG186140A1/en unknown
- 2011-06-24 TR TR2019/09709T patent/TR201909709T4/tr unknown
- 2011-06-24 AU AU2011269429A patent/AU2011269429B2/en active Active
- 2011-06-24 LT LTEP16020112.5T patent/LT3070091T/lt unknown
- 2011-06-24 WO PCT/DK2011/000069 patent/WO2011160632A1/en not_active Ceased
- 2011-06-24 SI SI201130896A patent/SI2585469T1/sl unknown
- 2011-06-24 KR KR1020137001855A patent/KR101864578B1/ko active Active
- 2011-06-24 DK DK11729889.3T patent/DK2585469T3/en active
- 2011-06-24 CN CN201180031069.5A patent/CN102958937B/zh active Active
- 2011-06-24 MX MX2012014131A patent/MX2012014131A/es active IP Right Grant
- 2011-06-24 CA CA2802895A patent/CA2802895C/en active Active
- 2011-06-24 TW TW100122303A patent/TWI507410B/zh active
- 2011-06-24 PL PL16020112T patent/PL3070091T3/pl unknown
- 2011-06-24 BR BR112012032813-1A patent/BR112012032813B1/pt active IP Right Grant
- 2011-06-24 RU RU2013103079/04A patent/RU2583787C2/ru active
- 2011-06-24 ES ES11729889.3T patent/ES2584055T3/es active Active
- 2011-06-24 LT LTEP11729889.3T patent/LT2585469T/lt unknown
- 2011-06-24 US US13/806,659 patent/US8980905B2/en active Active
- 2011-06-24 EP EP11729889.3A patent/EP2585469B1/en active Active
- 2011-06-24 HU HUE16020112 patent/HUE044301T2/hu unknown
-
2012
- 2012-11-28 IL IL223329A patent/IL223329A/en active IP Right Grant
- 2012-11-29 ZA ZA2012/09031A patent/ZA201209031B/en unknown
-
2014
- 2014-12-30 US US14/586,681 patent/US9273064B2/en active Active
-
2015
- 2015-10-01 US US14/872,487 patent/US9637499B2/en active Active
-
2016
- 2016-03-16 JP JP2016052707A patent/JP2016164168A/ja active Pending
- 2016-07-28 CY CY20161100745T patent/CY1117862T1/el unknown
-
2019
- 2019-06-21 HR HRP20191136TT patent/HRP20191136T1/hr unknown
- 2019-06-28 CY CY20191100679T patent/CY1122201T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603895A (en) | Novel phosphodiesterase inhibitors | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
| PH12015500441A1 (en) | Crystalline forms of 1-(5`-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3`h-spiro[azetidine-3,1`-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| EP3311818A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| NZ596579A (en) | Bace inhibitors | |
| AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| JO3265B1 (ar) | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض | |
| MA32604B1 (fr) | Composes organiques | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| TW200800975A (en) | New compounds 2 | |
| MX2012002179A (es) | Compuestos heterociclicos de oxima. | |
| MY162555A (en) | Pyrimidine derivatives having human neutrophil elastase inhibitory properties, and their use in therapy | |
| EA200900913A1 (ru) | Производное триазола в качестве ингибитора hsp90 | |
| WO2009026176A3 (en) | Antiinfective flavononol compounds and methods of use thereof | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| UA107583C2 (ru) | Спироциклические нитрилы как ингибиторы протеазы | |
| CL2008003854A1 (es) | Compuestos derivados de 2-bencilpiridazinona, inhibidores, reguladores y/o moduladores de met-quinasa; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de un tumor solido, de la sangre o del sistema inmune; kit farmaceutico que comprende una cantidad de dicho compuesto. | |
| WO2012046030A3 (en) | Phosphodiesterase inhibitors | |
| EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
| MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
| NZ600459A (en) | Amyloid binding agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20150602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2017 BY COMPUTER PACKAGES INC Effective date: 20160601 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20170531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2020 BY COMPUTER PACKAGES INC Effective date: 20190531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2021 BY COMPUTER PACKAGES INC Effective date: 20200603 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2022 BY IP CENTRUM LIMITED Effective date: 20210602 |
|
| ASS | Change of ownership |
Owner name: UNION THERAPEUTICS A/S, DK Effective date: 20210902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2023 BY IP CENTRUM LIMITED Effective date: 20220526 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2024 BY IP CENTRUM LIMITED Effective date: 20230531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2025 BY IP CENTRUM LIMITED Effective date: 20240531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JUN 2026 BY IP CENTRUM LIMITED Effective date: 20250613 |